KR101717280B1 - 게르마늄의 착체 화합물, 이를 제조하는 방법, 및 약물 - Google Patents

게르마늄의 착체 화합물, 이를 제조하는 방법, 및 약물 Download PDF

Info

Publication number
KR101717280B1
KR101717280B1 KR1020147035216A KR20147035216A KR101717280B1 KR 101717280 B1 KR101717280 B1 KR 101717280B1 KR 1020147035216 A KR1020147035216 A KR 1020147035216A KR 20147035216 A KR20147035216 A KR 20147035216A KR 101717280 B1 KR101717280 B1 KR 101717280B1
Authority
KR
South Korea
Prior art keywords
germanium
acid
complex compound
guanine
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147035216A
Other languages
English (en)
Korean (ko)
Other versions
KR20150011386A (ko
Inventor
알렉산드르 드미트리예비치 이사예프
이고르 발레리예비치 암브로소프
타마즈 오마로비치 마나쉐로프
스베틀라나 콘스탄티노브나 마텔로
Original Assignee
옵스체스트보 에스 오그라니첸노이 오트베트스트벤노스티유 "더블유디에스 파르마"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 옵스체스트보 에스 오그라니첸노이 오트베트스트벤노스티유 "더블유디에스 파르마" filed Critical 옵스체스트보 에스 오그라니첸노이 오트베트스트벤노스티유 "더블유디에스 파르마"
Publication of KR20150011386A publication Critical patent/KR20150011386A/ko
Application granted granted Critical
Publication of KR101717280B1 publication Critical patent/KR101717280B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/30—Germanium compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147035216A 2012-05-16 2012-11-01 게르마늄의 착체 화합물, 이를 제조하는 방법, 및 약물 Active KR101717280B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2012120329 2012-05-16
RU2012120329/04A RU2487878C1 (ru) 2012-05-16 2012-05-16 Комплексные соединения германия с производными азотистых оснований пуринового ряда, способы их получения и содержащие их лекарственные средства
PCT/RU2012/000897 WO2013172732A1 (ru) 2012-05-16 2012-11-01 Комплексные соединения германия, способы их получения и лекарственные средства

Publications (2)

Publication Number Publication Date
KR20150011386A KR20150011386A (ko) 2015-01-30
KR101717280B1 true KR101717280B1 (ko) 2017-03-17

Family

ID=48791166

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147035216A Active KR101717280B1 (ko) 2012-05-16 2012-11-01 게르마늄의 착체 화합물, 이를 제조하는 방법, 및 약물

Country Status (16)

Country Link
US (1) US9745337B2 (https=)
EP (1) EP2851368B1 (https=)
JP (1) JP5993088B2 (https=)
KR (1) KR101717280B1 (https=)
CN (1) CN104302651B (https=)
AU (1) AU2012380376B2 (https=)
BR (1) BR112014027919B1 (https=)
CA (1) CA2873390C (https=)
DK (1) DK2851368T3 (https=)
ES (1) ES2710915T3 (https=)
IN (1) IN2014DN09234A (https=)
PL (1) PL2851368T3 (https=)
PT (1) PT2851368T (https=)
RU (1) RU2487878C1 (https=)
TR (1) TR201901561T4 (https=)
WO (1) WO2013172732A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2626954C2 (ru) * 2015-11-11 2017-08-02 Общество С Ограниченной Ответственностью "Вдс Фарма" Комплексные соединения германия с аминокислотами и липоевой кислотой
RU2752934C1 (ru) * 2020-10-16 2021-08-11 Александр Дмитриевич Исаев Комплексные соединения германия с ациклическими полиолами и способ их получения
CN114133398B (zh) * 2021-12-31 2022-11-22 中南民族大学 氨基酸取代的阿昔洛韦类三环核苷衍生物及其合成方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3616208A (en) * 1967-09-29 1971-10-26 Parke Davis & Co Fermentation process for 9-(beta-d-arabinofuranosyl)adenine
JPS4924213B1 (https=) * 1969-04-02 1974-06-21
JPS4924213A (https=) 1972-06-19 1974-03-04
DE3212817A1 (de) * 1982-04-06 1983-10-13 Sanum-Kehlbeck GmbH & Co KG, 2812 Hoya Pharmazeutisch wirksame organische germaniumverbindungen und verfahren zu deren herstellung
EP0477871A3 (en) 1990-09-28 1992-12-02 Nippon Kayaku Kabushiki Kaisha Antiviral composition, containing guanine derivatives
CN1154359A (zh) * 1996-01-12 1997-07-16 常达正 氨基酸锗的制备方法及其应用
AU706703B2 (en) * 1996-09-05 1999-06-24 Primamedic Limited 1,3-dicarboxylic germanium complex and its therapeutic use
RU2104032C1 (ru) * 1997-03-11 1998-02-10 Общество с ограниченной ответственностью "Снежный барс" Способ усиления лечебного эффекта лекарственных средств
WO2000010561A1 (en) * 1998-08-17 2000-03-02 Evgeny Vladimirovich Soloviev Bio-chemical germanium complexes with high therapeutic efficiency and wide application spectrum
ATE226441T1 (de) 1999-02-22 2002-11-15 Gernot Treusch Therapeutisch wirksames stoffgemisch enthaltend s-acetylglutathion und aciclovir
RU2240792C2 (ru) 2002-07-30 2004-11-27 Государственное учреждение Научно-исследовательский институт вирусологии им. Д.И. Ивановского РАМН Комбинации на основе нетропсина или его бис-производного, обладающие антигерпетической активностью
RU2233280C1 (ru) 2003-03-25 2004-07-27 Научно-исследовательский институт физической и органической химии Ростовского государственного университета СОЛИ-10-ω-АРИЛОКСИАЛКИЛ-2,3,4,10-ТЕТРАГИДРОПИРИМИДО[1,2-A]БЕНЗИМИДАЗОЛА, ОБЛАДАЮЩИЕ МЕСТНОАНЕСТЕЗИРУЮЩИМ ДЕЙСТВИЕМ
DE10343365A1 (de) 2003-09-17 2005-04-14 Biosphings Ag Pharmazeutische Formulierungen von Xanthogenaten und Hemmstoffen der viralen Nukleinsäurereplikation
RU2476436C1 (ru) * 2012-01-25 2013-02-27 Общество С Ограниченной Ответственностью "Вдс Фарма" Комплексные соединения германия с аминокислотами и карбоновыми кислотами

Also Published As

Publication number Publication date
EP2851368A1 (en) 2015-03-25
JP5993088B2 (ja) 2016-09-14
WO2013172732A1 (ru) 2013-11-21
IN2014DN09234A (https=) 2015-07-10
US9745337B2 (en) 2017-08-29
ES2710915T3 (es) 2019-04-29
PT2851368T (pt) 2019-02-11
CN104302651B (zh) 2017-04-12
EP2851368B1 (en) 2019-01-02
CN104302651A (zh) 2015-01-21
BR112014027919A2 (pt) 2017-06-27
CA2873390C (en) 2017-10-24
PL2851368T3 (pl) 2019-06-28
DK2851368T3 (en) 2019-02-25
TR201901561T4 (tr) 2019-02-21
BR112014027919B1 (pt) 2020-02-04
EP2851368A4 (en) 2016-02-10
US20150126726A1 (en) 2015-05-07
AU2012380376B2 (en) 2015-10-01
RU2487878C1 (ru) 2013-07-20
JP2015518823A (ja) 2015-07-06
KR20150011386A (ko) 2015-01-30
CA2873390A1 (en) 2013-11-21
AU2012380376A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
JPH031309B2 (https=)
KR101717280B1 (ko) 게르마늄의 착체 화합물, 이를 제조하는 방법, 및 약물
AP620A (en) Uses of a flavin in the treatment of ill-effects caused by viral infections.
WO2013071696A1 (zh) 人体五种正常碱基在制备肿瘤药物中的应用
RU2573977C2 (ru) 4,6-ди(3,12-диаза-6,9-диазониадиспиро[5.2.5.2]гексадекан-1-ил)-2-метил-5-нитропиримидин тетрахлорид дигидрохлорид гексагидрат для лечения герпетической инфекции, фармацевтическая композиция для местного применения
ES2280259T3 (es) Complejos de galio de 3-hidroxi-4-pironas para tratar infecciones por procariotas intracelulares, virus de adn y retrovirus.
TW555559B (en) Combinations for the treatment of an HBV infection
US4093716A (en) Compositions containing 5-amino-5-deoxythymidine and pharmaceutically acceptable salts thereof
RU2185822C2 (ru) Препарат для лечения и профилактики вирусных заболеваний
ES2774663T3 (es) Agente para inducir interferón endógeno
AU2022203621B2 (en) Use of cyanobacterial biomass in treating hepatitis b virus infection
JPS63264527A (ja) 抗エイズウイルス剤
RU2694754C1 (ru) Противовирусная активность водного раствора фуллерена
RU2401121C1 (ru) Фармацевтическая композиция для лечения и профилактики вирусных инфекций и сифилиса на основе экстрактов растительного происхождения и способ лечения и профилактики вирусных инфекций и сифилиса
US20240342106A1 (en) Nanoparticles and uses thereof for treatment of human immunodeficiency virus
JP2000516962A (ja) ライノウイルス感染症の治療方法
JP2007505846A (ja) キサントゲン酸塩及びウイルス核酸複製の阻害剤（例えばアシクロビル）の医薬調製物
CN1491111A (zh) 抗病毒方法的应用
PL237937B1 (pl) Preparat farmaceutyczny do leczenia zakażenia wirusem herpes simplex

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20200227

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9